Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings

We recently published 10 Big Names Beating Wall Street at its Own Game. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Monday.

Recursion Pharmaceuticals soared by 13.99 percent on Monday to close at $6.68 apiece as investors resorted to bargain-hunting following a two-day drop, while repositioning portfolios ahead of earnings release.

Based on its historical reporting dates, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) will announce the results of its third quarter financial and operating highlights in the first week of November 2025.

To recall, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) incurred a 76 percent higher net loss in the second quarter of the year, at $171.9 million, versus the $97.5 million in the same period last year.

Revenues, on the other hand, increased by 33 percent to $19.2 million as compared with the $14.4 million year-on-year, with the bulk consisting primarily of revenues from collaboration agreements.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical stage biotechnology company leveraging sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry. It is among the few companies that technology giant Nvidia Corp. directly invested in.

While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.